Analysis of SOD1 activity in the blood and SOD1 protein concentration in the cerebrospinal fluid (CSF) of patients were the first biomarkers used for diagnosing ALS and as an endpoint in anti-SOD1 clinical drug trials10,11. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.